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BACKGROUND: Injectable contraceptive use is common, with 74 million users worldwide. Use of the injectable contraceptive depot medroxyprogesterone acetate (DMPA) is associated with bone mineral density loss. We hypothesize that increased bone resorption with DMPA use allows for mobilization of the toxic metal lead stored in bone to blood, presenting users with increased systemic exposure to lead.
OBJECTIVE: The objective of our study was to investigate the association between current DMPA use and blood lead concentrations.
METHODS: We conducted a cross-sectional analysis using enrollment data from the Study of Environment, Lifestyle & Fibroids (SELF), a cohort of
1,693 African-American women who were 23–35 years of age. Data on DMPA use were collected by computer-assisted telephone interview. Blood
lead concentrations were measured in whole blood samples among 1,548 participants (91% of cohort). We estimated the adjusted percent diﬀerence
in blood lead concentrations and 95% conﬁdence intervals (CI) between current DMPA users and nonusers using multivariable linear regression.
RESULTS: Geometric mean blood lead concentration was 0:69 lg=dL (95% CI: 0.67, 0.71). After adjustment, current DMPA users (7% of cohort) had
blood lead concentrations that were 18% higher than those of nonusers (95% CI: 8%, 29%). Similar associations were observed with additional analyses to assess for potential bias from smoking, DMPA-induced amenorrhea, use of estrogen-containing contraceptives, having given birth in the prior
year, and history of medical conditions or current medication use associated with bone loss.
DISCUSSION: Our results indicate that current DMPA use is associated with increased blood lead concentrations. Further research, particularly in populations highly exposed to lead, is warranted to consider tradeoﬀs between the adverse eﬀects of lead on human health and the importance of DMPA
as a contraceptive option to prevent unintended pregnancy. https://doi.org/10.1289/EHP7017

Introduction
Depot medroxyprogesterone acetate (DMPA) is an injectable
progestin-only contraceptive that is used in more than 90 countries
worldwide (Black et al. 2006). DMPA is an important contraceptive option to prevent unintended pregnancy; a single injection provides 3 months of eﬀective contraceptive coverage, with a
convenient dosing schedule and privacy (ACOG 2014). Since its
approval by the U.S. Food and Drug Administration (FDA) in
1992, DMPA has been used by one in ﬁve sexually active U.S.
women, with more frequent use reported among AfricanAmerican women (Daniels and Mosher 2013). Worldwide, the use
of injectable contraceptives is increasing, from 17 million users in
1994 to 74 million users in 2019 (United Nations 2019). However,
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unlike other progestin-only contraceptives, the inhibition of pituitary gonadotropin secretion by DMPA results in the substantial
reduction of ovarian estrogen production (Bahamondes et al. 2000,
2014; Clark et al. 2001; Miller et al. 2000), with one study reporting a mean weekly estradiol level among DMPA users similar to
that observed in postmenopausal women (Clark et al. 2001;
Randolph et al. 2011). Just as estrogen deﬁciency after menopause
increases bone resorption and bone loss (Lobo 2014), lower bone
mineral density has been observed during DMPA use (Nappi et al.
2012). The recovery of bone mineral density after discontinuation
of DMPA has minimized some of the concerns posed by the FDA
black box warning on the potential loss of bone mineral density
with prolonged use (ACOG 2014; Vondracek et al. 2009).
However, ramiﬁcations other than bone health from increased
bone resorption may exist.
Increased bone resorption during DMPA use may present users
with increased systemic exposure to the toxic metal lead. More
than 90% of lead that enters the body from exogenous exposure is
stored in the skeleton (Barry 1975). Although lead has a long elimination time from bone (1–2 decades) in comparison with blood
(1 month) (Abadin et al. 2007), lead can transfer between bone and
other tissue compartments and blood; it is estimated that bone lead
contributes 45%–70% of lead in blood (Gulson et al. 1995), providing an endogenous source of blood lead. Increased blood lead concentrations have been associated with other hypoestrogenic states
during which increased bone resorption occurs, such as menopause
and lactation (Gulson et al. 1998, 2003; Hernandez-Avila et al.
2000; Nash et al. 2004; Silbergeld et al. 1988; Symanski and
Hertz-Picciotto 1995). The potential for increased mobilization of
lead from bone to systemic circulation during DMPA use is of public health concern. There is widespread scientiﬁc consensus that
there are no safe levels of lead in blood. Lead can adversely aﬀect

117004-1

128(11) November 2020

all organ systems, even in adulthood, with neurological, renal, cardiovascular, hematological, immunological, and reproductive
eﬀects being well-documented (Abadin et al. 2007; ATSDR
2019).
To our knowledge, the association between current DMPA
use and blood lead concentrations has been examined in only one
study. In a cross-sectional study of 174 adolescent clinic patients,
higher mean blood lead concentrations were reported among
DMPA users compared with concentrations among oral contraceptive users and nonhormonal contraceptive users (Iglesias et al.
2008). However, that study included only 28 current DMPA
users, and analyses were not adjusted for potential confounders,
such as smoking, that substantially contribute to the concentration of lead in blood (Abadin et al. 2007). Hence, the purpose of
the present study was to investigate the association between current DMPA use and blood lead concentrations using data from a
large cohort of young African-American women for whom extensive covariate data were available.

Methods
Study Population
We conducted a cross-sectional analysis using enrollment data
from the Study of Environment, Lifestyle & Fibroids (SELF).
SELF is an ongoing prospective cohort study of 1,693 AfricanAmerican women designed to identify risk factors for ﬁbroid
incidence and growth as previously described (Baird et al. 2015).
Brieﬂy, African-American women ages 23–35 y residing in the
Detroit, Michigan, area were enrolled in SELF from 2010 to
2012. To reach a diverse sample of African-American women
from the area, broad recruitment strategies were employed,
including the use of a study website, ﬂiers, brochures at health
care clinics, local radio, television, newspaper advertisements, information booths at community events, and letters describing the
study to African-American women who had been seen at the
Henry Ford Health System, a collaborating institution in Detroit.
The primary eligibility criteria included having an intact uterus
and having no prior clinical diagnosis of ﬁbroids, cancer that
required radiation or chemotherapy, or the autoimmune diseases
lupus, Grave’s disease, Sjogren’s, scleroderma, or multiple sclerosis requiring medication. The parent SELF study was approved
by institutional review boards at the National Institute of
Environmental Health Sciences and Henry Ford Health System.
The present analyses used deidentiﬁed SELF data and was
deemed not to involve human subjects by the Human Research
Protection Program at Michigan State University.
At enrollment, participants attended a clinic visit in which
trained study personnel measured each participant’s height and
weight and collected biological samples, including blood samples
that were analyzed for hemoglobin (g/dL) (Baird et al. 2015) and
serum 25-hydroxyvitamin D (25(OH)D) (Jukic et al. 2016); the
annual mean 25(OH)D was estimated using a cosinor model to
account for seasonal changes (Jukic et al. 2016). Participants also
completed computer-assisted telephone and web-based interviews and self-administered questionnaires, including the Block
2005 Food Frequency Questionnaire (Baird et al. 2015). These
study activities were used to ascertain information on demographics, lifestyle behaviors, and diet, as well as reproductive,
medical, and contraceptive history.

DMPA Use
During the computer-assisted telephone interview at enrollment,
hormonal contraceptive data were collected, including whether
the participant had ever used “hormone shots like DepoEnvironmental Health Perspectives

Provera.” If the participant responded yes, then she was asked
whether she was currently using hormone shots like DepoProvera®. DMPA injectable contraceptives (150 mg=1:0 mL
intramuscular or 104 mg=0:65 mL subcutaneous) were the only
FDA-approved injectable contraceptives in the United States at
the time of the SELF enrollment, and both formulations are associated with similar changes in bone mineral density (Kaunitz et al.
2009). However, the intramuscular formulation is primarily used
in the United States (Upadhyay et al. 2016). Each participant was
also asked about the total duration of DMPA use over her lifetime, because DMPA use can be episodic; data were not collected
on the duration of the current episode of DMPA use. If a participant had discontinued DMPA use, she was asked about the age at
last use. In the present analyses, the exposure of interest was current DMPA use. Women not currently using DMPA were deﬁned
as nonusers, and this comparison group included both past
DMPA users and never users. This comparison group was used
to avoid selection bias that may transpire with the use of never
users. Only 57% of participants reported never using DMPA, and
these participants tend to have higher socioeconomic status,
which is associated with lower blood lead concentrations, in comparison with current and past DMPA users.

Blood Lead Concentrations
Nonfasting whole blood samples were collected at enrollment in a
manner that was in accord with recommendations by the U.S. Centers
for Disease Control and Prevention (CDC) to limit metal contamination and promote specimen stability (CDC 2016). Speciﬁcally, venipuncture was performed using a stainless-steel needle, and the whole
blood sample was collected in a vacutainer that was prescreened for
metal contamination. In addition, the whole blood sample used for the
laboratory analysis of blood lead concentrations was the ﬁrst blood
specimen collected. After collection, the sample was not further processed and was permanently stored at the National Institute of
Environmental Health Sciences Repository, Experimental Pathology
Laboratories, Inc. at −20 C (Baird et al. 2015). Whole blood samples
were available for 1,664 participants (98% of the original cohort of
1,693 participants). Lead was quantiﬁed by inductively coupled
dynamic reaction cell plasma mass spectrometry (ICP-DRC-MS)
(CDC 2016) by the Inorganic and Radiation Analytical Toxicology
Branch Laboratory, Division of Laboratory Science, National Center
for Environmental Health at the CDC. Of the 1,664 participants, samples for 116 participants could not be analyzed due to sample clotting,
resulting in a sample size of 1,548 women for the present analyses.
Only one participant had a blood lead concentration below the limit of
detection (LOD; 0:07 lg=dL); for that participant, we used the value
of the LOD divided by the square root of 2 (0:05 lg=dL) (Hornung
and Reed 1990).

Statistical Analyses
For descriptive purposes, we compared participant characteristics
at enrollment between current DMPA users and nonusers. We
also estimated the geometric mean blood lead concentration,
adjusted for age and smoking, and accompanying 95% conﬁdence
interval across categories of participant characteristics among
nonusers of DMPA.
To evaluate the association between current DMPA use and
blood lead concentrations, we conducted multivariable linear
regression and estimated the percent diﬀerence in blood lead concentrations and accompanying 95% conﬁdence intervals, comparing current DMPA users with nonusers. Speciﬁcally, we modeled
the natural log of the blood lead concentrations and estimated the
percent diﬀerence using the formula ½exp ðbetaÞ − 1 × 100.
Informed by prior studies reporting factors associated with DMPA
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use and exposure sources of lead (Abadin et al. 2007; ATSDR
2019; Scholes et al. 1999, 2002), we identiﬁed variables for adjustment in the regression model. We adjusted for participant age (continuous), education (≤HS=GED, some college/Associate’s degree,
Bachelor’s/Master’s/doctoral degree), current smoking (yes, no),
and alcohol use in the last year (none, moderate, heavy) (see Model
1 in Table 2). We repeated the analyses, additionally adjusting for
factors associated with bone health, including having given birth in
the previous year (yes, no), log2 -transformed estimated annual
mean 25(OH)D concentrations (continuous), estimated total calcium intake (<800, ≥800 mg=d), and a composite variable (yes,
no) for history of medical conditions or current medication use
associated with bone loss (thyroid condition, anorexia nervosa,
irritable bowel syndrome, anticonvulsant, thyroid hormone
replacement, heparin, glucocorticoid medication use) (see Model 2
in Table 2) (Vondracek et al. 2009; U.S. Department of Health and
Human Services 2004). Current medication use was informed by
the prescription medications participants brought to the clinic visit
and used in the prior 24 h.
We conducted several sensitivity analyses. First, we restricted
the study population to never smokers (n = 1,139) to evaluate the
adequacy of adjusting for smoking in the main analyses. Second,
we repeated the analyses, adjusting for hemoglobin (continuous)
because blood lead is stored in red blood cells (Abadin et al.
2007) and current DMPA users are less likely to be anemic due
to DMPA-induced amenorrhea (Hubacher et al. 2009; Schwallie
and Assenzo 1973). Third, we compared current DMPA users to
those who had used DMPA in the past but were not currently
using this contraceptive method. We conducted this sensitivity
analysis to address the concern that an observed association may
be due to unmeasured risk factors for lead exposure that might be
more common among current DMPA users than nonusers. For
this sensitivity analysis, we restricted past DMPA users to those
who had discontinued use 3 or more years prior to the enrollment
visit to correspond with the recovery of bone mass after discontinuation (Scholes et al. 2002). Fourth, we repeated the analyses,
restricting the study population to those not currently using
estrogen-containing contraception (n = 1,332) because prior studies of combined hormonal contraception and bone mineral density have reported mixed results (Liu and Lebrun 2006; Martins
et al. 2006). Fifth, we restricted the study population to those
who had not given birth in the previous year. This sensitivity
analysis was conducted to exclude women who may have
increased blood lead concentrations from bone resorption during
the later stages of pregnancy or lactation (Abadin et al. 2007).
Last, we conducted an analysis excluding study participants with
a history of medical conditions or current medication use associated with bone loss.
We also conducted an exploratory analysis to evaluate the
dose–response relationship between current DMPA use and
blood lead. In this analysis, we compared current DMPA users
with a lifetime duration of DMPA use of greater than 1 y, current
DMPA users with a lifetime use of DMPA ≤1 y, and women not
currently using DMPA. Although total lifetime duration of
DMPA use is not a proxy for duration of current use because
women may start, stop, and restart DMPA use, it is likely that
current DMPA users with a lifetime use of DMPA ≤1 y have
only used DMPA for a short while. However, some current users
with >1 y of lifetime use may have re-started DMPA use only
recently.

Results
At enrollment, 7% of participants (n = 102) reported current DMPA
use. Among current DMPA users, the median duration of lifetime
use was 5 y [interquartile range (IQR): 2–9], with a maximum of
Environmental Health Perspectives

15 y of lifetime use reported. Current DMPA users tended to be
younger and had lower educational attainment, household income,
alcohol consumption, and body mass index in comparison with nonusers (Table 1). Current DMPA users were more likely to report
greater total intake of calcium and having given birth in the past year
and had higher hemoglobin levels than nonusers.
The geometric mean blood lead concentration in the overall
cohort was 0:69 lg=dL [95% conﬁdence interval (CI): 0.67, 0.71],
and two participants had blood lead concentrations ≥5 lg=dL.
The geometric mean blood lead concentrations in the SELF was
higher than that of non-Hispanic black (0:60 lg=dL, 95% CI:
0.53, 0.68) and white women (0:53 lg=dL, 95% CI: 0.48, 0.59) of
the same age in the National Health and Nutrition Examination
Survey for years 2011–2012 (Table S1) (https://wwwn.cdc.gov/
nchs/nhanes/continuousnhanes/overview.aspx?BeginYear=2011).
Among participants not currently using DMPA, those with higher
blood lead concentrations tended to be older and have lower educational attainment and household income. They were also more
likely to smoke, consume alcohol, have given birth in the past year
and be currently lactating, and to have had a history of high blood
lead concentrations as an infant or child (Table 1).
The geometric mean and distribution of blood lead concentrations was higher for current DMPA users (0:83 lg=dL, 95% CI:
0.75, 0.93) than nonusers (0:68 lg=dL, 95% CI: 0.66, 0.70)
(Table 2, Table S2, Figure S1). After multivariable adjustment,
current users of DMPA at enrollment had blood lead concentrations that were 18% higher than those of nonusers (95% CI: 8%,
29%) (Table 2). A post hoc analysis using total annual household
income (<$20,000, $20,000 − $50,000, >$50,000) instead of
education yielded nearly identical results (Table S3). We also
observed a similar percent diﬀerence in blood lead concentrations
in each of our sensitivity analyses in which we: a) restricted the
study population to never smokers (19% higher, 95% CI: 8%,
32%); b) additionally adjusted for hemoglobin (17% higher, 95%
CI: 7%, 28%); c) compared current DMPA users with past
DMPA users who had discontinued ≥3 y prior to enrollment
(15% higher, 95% CI: 4%, 28%); d) restricted the study population to those not currently using estrogen-containing contraception (16% higher, 95% CI: 6%, 27%); e) restricted the study
population to women who had not given birth in the previous
year (16% higher, 95% CI: 5%, 28%); and f) excluded participants
with a history of medical conditions or current medication use
associated with bone loss (20% higher, 95% CI: 9%, 32%).
In our exploratory analysis of the dose–response relationship,
current users of DMPA who have used DMPA for more than 1 y
in their lifetime had blood lead concentrations that were 20%
higher than those of nonusers (95% CI: 9%, 33%), whereas current DMPA users who have used DMPA for 1 y or less in their
lifetime had blood lead concentrations that were 8% higher,
although accompanied by a wide conﬁdence interval (95% CI:
−11%, 31%) (Table S4).

Discussion
In our study sample, current DMPA use was associated with
increased blood lead concentrations. This association is biologically plausible. DMPA acts centrally at the level of the hypothalamus and pituitary to inhibit gonadotropin secretion, resulting in
the suppression of ovarian estradiol production. Substantially
lower serum estradiol concentrations have been reported after the
initiation of DMPA use (Miller et al. 2000) and when comparing
DMPA users with nonusers (Bahamondes et al. 2000, 2014). One
study, in which serum estradiol concentrations were measured
weekly during a 13-wk DMPA contraceptive coverage period,
reported a mean serum estradiol concentration of 18:9 pg=mL
(Clark et al. 2001), a concentration similar to that observed
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Table 1. Participant characteristics at enrollment by current depot medroxyprogesterone acetate use and blood lead concentrations, Study of Environment,
Lifestyle & Fibroids, 2010–2012 (n = 1,548).
Current DMPA usea
Characteristic
Age at enrollment visit (y)c
23–25
26–28
29–31
32–35
Educationd
≤HS or GED
Some college or Associate’s/technical degree
Bachelor’s, Master’s, or doctoral degree
Total annual household income (USD$)d
<20,000
20,000–50,000
>50,000
Smoking statuse
Never
Former
Current <10 cigarettes/d
Current ≥10 cigarettes/d
Alcohol consumption last year
None
Moderate
Heavy
Body mass index (kg=m2 )
<25:0
25.0 to <30:0
30.0 to <35:0
35.0 to <40:0
≥40:0
Exercise in past 12 monthsd
Low
Low to moderate
Moderate
High
Very high
Daily total calcium intake (mg/d) during prior yearf
Low (<800 mg=d)
High (≥800 mg=d)
Estimated annual mean 25(OH)D concentration
<Median (15:31 ng=mL)
≥Median (15:31 ng=mL)
Conditions or medication use associated with bone lossg
No
Yes
Birth in last year
No
Yes, not currently lactating
Yes, currently lactating
Low hemoglobin (<12 g=dL)d
No
Yes
Told by doctor had high lead levels when infant or childd
No
Yes

Yes n = 102
n (%)

Blood lead (lg=dL)

No n = 1,446
n (%)

Among women not currently using DMPA
(n = 1,446) Adjusted GM (95% CI)b

31 (30)
26 (25)
24 (24)
21 (21)

319 (22)
367 (25)
385 (27)
375 (26)

0.65 (0.62, 0.69)
0.68 (0.65, 0.72)
0.68 (0.65, 0.71)
0.71 (0.68, 0.74)

36 (35)
50 (49)
16 (16)

296 (20)
723 (50)
426 (29)

0.80 (0.76, 0.84)
0.69 (0.66, 0.71)
0.60 (0.58, 0.63)

66 (65)
27 (26)
9 (9)

632 (44)
545 (38)
258 (18)

0.75 (0.73, 0.78)
0.64 (0.62, 0.67)
0.61 (0.58, 0.64)

76 (75)
6 (6)
14 (14)
6 (6)

1,063 (74)
107 (7)
203 (14)
73 (5)

0.60 (0.59, 0.62)
0.73 (0.67, 0.79)
1.03 (0.97, 1.09)
1.18 (1.07, 1.31)

41 (40)
44 (43)
17 (17)

414 (29)
740 (51)
292 (20)

0.64 (0.62, 0.67)
0.67 (0.65, 0.69)
0.77 (0.73, 0.82)

39 (38)
22 (22)
13 (13)
6 (6)
22 (22)

278 (19)
308 (21)
282 (20)
247 (17)
331 (23)

0.69 (0.65, 0.73)
0.70 (0.67, 0.74)
0.67 (0.63, 0.71)
0.69 (0.65, 0.73)
0.66 (0.63, 0.69)

11 (11)
29 (29)
30 (30)
17 (17)
14 (14)

227 (16)
329 (23)
386 (27)
282 (20)
218 (15)

0.64 (0.61, 0.68)
0.68 (0.65, 0.72)
0.71 (0.68, 0.74)
0.66 (0.63, 0.70)
0.70 (0.66, 0.75)

44 (43)
58 (57)

771 (53)
675 (47)

0.68 (0.65, 0.70)
0.69 (0.66, 0.71)

52 (51)
50 (49)

719 (50)
722 (50)

0.70 (0.68, 0.72)
0.67 (0.64, 0.69)

89 (87)
13 (13)

1,319 (91)
127 (9)

0.68 (0.67, 0.70)
0.65 (0.60, 0.71)

85 (83)
14 (14)
3 (3)

1,362 (94)
74 (5)
10 (1)

0.68 (0.66, 0.69)
0.77 (0.70, 0.86)
0.86 (0.65, 1.14)

89 (87)
13 (13)

1,003 (70)
421 (30)

0.69 (0.67, 0.71)
0.66 (0.63, 0.69)

99 (100)
0 (0)

1,343 (98)
28 (2)

0.68 (0.66, 0.69)
0.79 (0.67, 0.94)

Note: CI, confidence interval; DMPA, depot medroxyprogesterone acetate; GED, general equivalency diploma; GM, geometric mean; HS, high school; 25(OH)D, 25-hydroxyvitamin D.
a
At enrollment visit.
b
Geometric mean blood lead concentration adjusted for age (continuous) and current smoking (yes, no).
c
Geometric mean blood lead concentration adjusted only for current smoking (yes, no).
d
Missing data on education (n = 0 exposed, n = 1 unexposed); annual household income (n = 0 exposed, n = 11 unexposed), exercise (n = 1 exposed, n = 4 unexposed); estimated annual mean 25(OH)D concentration (n = 0 exposed, n = 5 unexposed); hemoglobin (n = 0 exposed, n = 22 unexposed); told by doctor had high lead levels when infant or child (n = 3
exposed, n = 75 unexposed).
e
Geometric mean blood lead concentration adjusted only for age (continuous).
f
Total calcium intake includes intake from both dietary and supplement sources.
g
Self-reported history of medical conditions (thyroid condition, anorexia, irritable bowel syndrome) or current medication use (anticonvulsant, thyroid hormone replacement, heparin,
or glucocorticoid) associated with bone health.

among postmenopausal women (Randolph et al. 2011). The
reduction in estrogen contributes to the well-documented association between DMPA use and lower bone mineral density (Lobo
2014; Nappi et al. 2012). Bone is the primary storage site for lead
Environmental Health Perspectives

(Silbergeld et al. 1993), and increased bone resorption during
DMPA use allows for the mobilization of lead from bone stores
to blood. Increased blood lead levels have been observed during
other periods of increased bone resorption, including lactation
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Table 2. Percent difference (95% CI) in geometric mean of blood lead concentrations between current depot medroxyprogesterone acetate (DMPA) users and
nonusers, Study of Environment, Lifestyle & Fibroids, 2010–2012.
Current
DMPA use
No
Yes
Restricted to never smokers (n = 1,139)
No
Yes
No
Additional hemoglobin adjustment (n = 1,526)c
Yes
Past use
Past DMPA users as unexposed group (n = 546)d,e
Current use
Excluding current users of estrogen-containing contraception No
(n = 1,332)
Yes
Restricted to women who had not given birth in prior year
No
(n = 1,447)
Yes
Restricted to women without a history of medical conditions No
or current medication use associated with bone loss
Yes
(n = 1,408)

Analyses
Main analysis (n = 1,548)

Model 2b
Crude blood lead
Model 1a
n (%)
(lg=dL) GM (95% CI) % difference (95% CI) % difference (95% CI)
1,446 (93)
0.68 (0.66, 0.70)
Ref
Ref
102 (7)
0.83 (0.75, 0.93)
19 (9, 30)
18 (8, 29)
1,063 (93)
0.60 (0.59, 0.62)
Ref
Ref
76 (7)
0.76 (0.67, 0.86)
21 (9, 34)
19 (8, 32)
1,424 (93)
0.68 (0.67, 0.70)
Ref
Ref
102 (7)
0.83 (0.75, 0.93)
18 (8, 29)
17 (7, 28)
444 (81)
0.75 (0.71, 0.78)
Ref
Ref
102 (19)
0.83 (0.75, 0.93)
17 (5, 29)
15 (4, 28)
1,233 (93)
0.70 (0.68, 0.72)
Ref
Ref
99 (7)
0.84 (0.75, 0.94)
17 (7, 29)
16 (6, 27)
1,362 (94)
0.68 (0.66, 0.70)
Ref
Ref
85 (6)
0.81 (0.71, 0.92)
16 (5, 27)
16 (5, 28)f
1,319 (94)
0.68 (0.67, 0.70)
Ref
Ref
89 (6)
0.85 (0.76, 0.96)
22 (11, 34)
20 (9, 32)g

Note: CI, confidence interval; DMPA, depot medroxyprogesterone acetate; GM, geometric mean; Ref, reference.
a
Adjusted for age (continuous), education (≤HS=GED, some college/Associate’s degree, Bachelor’s/Master’s/doctoral degree), current smoking (yes, no), and alcohol use in last year
(none, moderate, heavy).
b
Adjusted for age (continuous), education (≤HS=GED, some college/Associate’s degree, Bachelor’s/Master’s/doctoral degree), current smoking (yes, no), alcohol use in last year
(none, moderate, heavy), birth in last year (yes, no), log2 -transformed estimated annual mean 25(OH)D concentrations (continuous), total calcium intake (<800, ≥800 mg=d) and selfreported history of medical conditions (thyroid condition, anorexia, irritable bowel syndrome) or current medication use (anticonvulsant, thyroid hormone replacement, heparin, or glucocorticoid) associated with bone health (yes, no).
c
Hemoglobin data missing for 22 women not currently using DMPA.
d
Past DMPA users who discontinued ≥3 y prior to enrollment. Median time since discontinuing DMPA use was 8 y (interquartile range: 5–11 y).
e
Total lifetime months of use for past DMPA users was median 12 months (interquartile range: 6–36 months) and for current DMPA users was median 60 months (interquartile range:
24–108 months).
f
Variable birth in last year (yes, no) not included in multivariable model.
g
Variable self-reported history of medical conditions or current medication use associated with bone health (yes, not) not included in multivariable model.

and menopause (Gulson et al. 1998, 2003; Hernandez-Avila et al.
2000; Nash et al. 2004; Silbergeld et al. 1988; Symanski and
Hertz-Picciotto 1995).
Our ﬁnding is consistent with the prior study that examined this
association. A small cross-sectional study was conducted among
adolescent clinic patients ages 13–21 y seeking care at a medical
center in the Bronx, New York (Iglesias et al. 2008). Iglesias et al.
(2008) reported higher mean blood lead concentrations among current DMPA users (n = 28) compared with current oral contraceptive pill users (n = 25), and nonhormonal contraceptive users
(n = 121). However, the analyses were not adjusted for factors that
may confound the association.
The present study beneﬁted from the rich data available for the
adjustment of confounding factors, including age, smoking, education, alcohol use, and recent birth, and the pursuit of detailed sensitivity analyses. We were able to thoroughly investigate potential
sources of bias and demonstrate robust results across the sensitivity
analyses. It is substantially larger than the prior study, and it is the
ﬁrst study among African-American women in their 20s and 30s
for whom DMPA has been available as a contraceptive for most of
their reproductive lives. In addition, the misclassiﬁcation of current
DMPA use is likely minimal because the administration of DMPA
in the United States requires a health care visit and an intramuscular injection, and this visit would have transpired in the 3 months
before the enrollment visit.
Our study had several limitations. Given the cross-sectional
study design, it is possible that greater exogenous lead exposure
among current DMPA users, compared with nonusers, may
explain our results. In this study, data on well-established sources
of lead exposure, including residence in older housing with deteriorating lead-based paint and consumption of contaminated
drinking water, were not available (ATSDR 2019). Hence, sources of lead exposure that may be associated with DMPA use may
not be fully accounted for by our adjustment factors, leading to
the possibility of residual confounding. However, in our analyses
using past DMPA users as the comparison group—a group that
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would be expected to be more similar to current DMPA users
with regard to measured and unmeasured risk factors for lead exposure—current users had appreciably higher blood lead concentrations than past users. This ﬁnding suggests that unmeasured
factors related to women choosing to use DMPA did not introduce bias in the present analysis. It is also possible that the
observed increase in blood lead concentrations with DMPA use
may partly be due to amenorrhea that accompanies DMPA use
and the reduced loss of red blood cells where lead resides in
blood (Abadin et al. 2007). However, an analysis with additional
adjustment for hemoglobin yielded an estimate of association
similar to that of the main analyses, minimizing this concern.
In this study we were also limited by the lack of data on duration of current DMPA use. These data would have provided
insight into whether the release of lead from bone into blood
mirrors the pattern of bone loss observed with DMPA use, with
loss being greatest in the ﬁrst 2 y after DMPA initiation and
then continuing at a slower rate with longer use (d’Arcangues
2006). The results from our exploratory analyses suggest a
dose–response relationship, although cautious interpretation of
these results is warranted. Only 21 SELF participants were current DMPA users with 1 y or less lifetime use of DMPA. There
is also the potential for misclassiﬁcation because current users
with more than 1 y of lifetime DMPA use could have recently
restarted the method.
Further research is warranted to conﬁrm our ﬁndings.
Additionally, data are needed on the relationship between duration of DMPA use and blood lead concentrations, given that
reproductive-age women may use DMPA for a substantial number of years between menarche and menopause. Information on
consecutive months of DMPA use at the time of discontinuation
would also allow for the investigation of the decline of blood
lead levels with recovery of bone mineral density.
If our ﬁndings are replicated, an understanding of the public health
impact of increased blood lead concentrations with DMPA use will
be imperative from both the environmental and reproductive justice
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perspectives. In the United States, the social and economic
inequities that contribute to the disproportionate exposure to lead
are also associated with DMPA use. There is widespread scientiﬁc consensus that no safe levels of blood lead exist and even
low blood lead levels in adults have been linked to a range of
adverse outcomes (Abadin et al. 2007). Yet, DMPA is an important contraceptive option for the prevention of pregnancy, management of menstrual pain, and treatment of pelvic pain
associated with endometriosis (ACOG 2014, 2018; Barra et al.
2018; Buggio et al. 2017).
In addition, research is warranted to understand how our ﬁndings translate to communities and countries where the general
population is exposed to higher environmental lead contamination. In the SELF, most participants had blood lead concentrations below the actionable level of 5 lg=dL set by the CDC. In
contrast, mean blood lead concentrations markedly exceeding
5 lg=dL have been reported in studies of reproductive-age
women in Kenya, Nigeria, and Ethiopia (Bede-Ojimadu et al.
2018). In these same countries, DMPA is the most commonly
used hormonal contraceptive method (Tsui et al. 2017), playing a
critical role in the prevention of unintended pregnancy. It is also
important to understand the impact of postpartum DMPA use in
breastfeeding women on infant lead exposure. DMPA can generally be administered early in the postpartum period in breastfeeding women, immediately after delivery in the United States
(Curtis et al. 2016) or 6 wk postpartum in other countries (WHO
2015). Lead in breastmilk is transferred to infants, contributing to
infant exposure to lead (Ettinger et al. 2014).
In conclusion, our data indicate an association between current DMPA use and increased blood lead concentrations. Further
research, particularly in populations highly exposed to lead, is
warranted to conﬁrm our ﬁndings and to consider the tradeoﬀs
between the adverse eﬀects of lead on human health and the importance of DMPA as a contraceptive option to prevent unintended pregnancy.
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